Total raised
$20.0M
Last: Series A 2017-06
Stage
Series A
Founded
2016
Headcount
6
HQ
Sector
Health Tech & Life Sciences
About
Mitoconix Bio is developing a strategy for improving mitochondrial health as a disease-modifying therapeutic for neurodegenerative diseases. The companys lead drug is an inhibitor of pathological mitochondrial fragmentation and dysfunction. The drug has demonstrated in vivo efficacy in animal models of Huntingtons disease and Parkinsons disease, and it has shown beneficial activity in patient-derived cells of Huntingtons disease, sporadic and genetic Parkinsons disease, and sporadic and genetic Alzheimers disease.
Funding history · 2 rounds · $20.0M total
2017-06
Series A
$20.0M
2016-08
Undisclosed
Undisclosed
Company Intelligence Q&A
Structured intelligence from startupim data — optimized for AI retrieval and grounding.
- What is Mitoconix Bio's primary focus in drug development?
- Mitoconix Bio is developing a strategy to improve mitochondrial health as a disease-modifying therapeutic for neurodegenerative diseases.
- What is the status of Mitoconix Bio as of July 2019?
- Mitoconix Bio became inactive and ceased to operate in July 2019.
- When was Mitoconix Bio founded?
- Mitoconix Bio was founded in June 2016.
- What was Mitoconix Bio's total raised capital?
- Mitoconix Bio raised a total of $20,000,000 USD.
- Which investors participated in Mitoconix Bio's Series A funding round in June 2017?
- Mitoconix Bio's Series A round in June 2017 included investors such as RMGP Biopharma Investment Fund and Arix Bioscience. For a full list of investors, please refer to startupim.
- What is the lead drug developed by Mitoconix Bio?
- Mitoconix Bio's lead drug is an inhibitor of pathological mitochondrial fragmentation and dysfunction.
- In which animal models and patient-derived cells has Mitoconix Bio's drug shown efficacy?
- The drug has demonstrated in vivo efficacy in animal models of Huntington's disease and Parkinson's disease, and beneficial activity in patient-derived cells of Huntington's disease, sporadic and genetic Parkinson's disease, and sporadic and genetic Alzheimer's disease.
- How many employees did Mitoconix Bio have?
- Mitoconix Bio had between 1 and 10 employees, with an exact count of 6.
Sectors & technology
Primary sector
Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & Development
Target customers
Healthcare & Life SciencesLife SciencesPharmaceuticals
Business model
B2B
Highlights
1 Patents
Tags
pharmaceuticalsneurologyalzheimers-diseaseparkinson